BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 21064111)

  • 1. Age as a key factor influencing metastasizing patterns and disease-specific survival after sentinel lymph node biopsy for cutaneous melanoma.
    Kretschmer L; Starz H; Thoms KM; Satzger I; Völker B; Jung K; Mitteldorf C; Bader C; Siedlecki K; Kapp A; Bertsch HP; Gutzmer R
    Int J Cancer; 2011 Sep; 129(6):1435-42. PubMed ID: 21064111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sentinel lymph node biopsy in patients with thin primary cutaneous melanoma.
    Murali R; Haydu LE; Quinn MJ; Saw RP; Shannon K; Spillane AJ; Stretch JR; Thompson JF; Scolyer RA
    Ann Surg; 2012 Jan; 255(1):128-33. PubMed ID: 21975320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patterns of initial recurrence and prognosis after sentinel lymph node biopsy and selective lymphadenectomy for melanoma.
    Wagner JD; Ranieri J; Evdokimow DZ; Logan T; Chuang TY; Johnson CS; Jung SH; Wenck S; Coleman JJ
    Plast Reconstr Surg; 2003 Aug; 112(2):486-97. PubMed ID: 12900606
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical impact of sentinel lymph node biopsy in patients with thick (>4 mm) melanomas.
    White I; Fortino J; Curti B; Vetto J
    Am J Surg; 2014 May; 207(5):702-7; discussion 707. PubMed ID: 24791630
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sentinel node status in melanoma patients is not predictive for overall survival upon multivariate analysis.
    Roka F; Kittler H; Cauzig P; Hoeller C; Hinterhuber G; Wolff K; Pehamberger H; Diem E
    Br J Cancer; 2005 Feb; 92(4):662-7. PubMed ID: 15700039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lymphatic invasion identified by monoclonal antibody D2-40, younger age, and ulceration: predictors of sentinel lymph node involvement in primary cutaneous melanoma.
    Niakosari F; Kahn HJ; McCready D; Ghazarian D; Rotstein LE; Marks A; Kiss A; From L
    Arch Dermatol; 2008 Apr; 144(4):462-7. PubMed ID: 18427039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic factors in melanoma patients with tumor-negative sentinel lymph nodes.
    Egger ME; Bhutiani N; Farmer RW; Stromberg AJ; Martin RC; Quillo AR; McMasters KM; Scoggins CR
    Surgery; 2016 May; 159(5):1412-21. PubMed ID: 26775577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The sentinel lymph node status is an important factor for predicting clinical outcome in patients with Stage I or II cutaneous melanoma.
    Statius Muller MG; van Leeuwen PA; de Lange-De Klerk ES; van Diest PJ; Pijpers R; Ferwerda CC; Vuylsteke RJ; Meijer S
    Cancer; 2001 Jun; 91(12):2401-8. PubMed ID: 11413531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Should all patients with melanoma between 1 and 2 mm Breslow thickness undergo sentinel lymph node biopsy?
    Mays MP; Martin RC; Burton A; Ginter B; Edwards MJ; Reintgen DS; Ross MI; Urist MM; Stromberg AJ; McMasters KM; Scoggins CR
    Cancer; 2010 Mar; 116(6):1535-44. PubMed ID: 20108306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regression does not predict nodal metastasis or survival in patients with cutaneous melanoma.
    Burton AL; Gilbert J; Farmer RW; Stromberg AJ; Hagendoorn L; Ross MI; Martin RC; McMasters KM; Scoggins CR; Callender GG
    Am Surg; 2011 Aug; 77(8):1009-13. PubMed ID: 21944515
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sentinel lymph node biopsy in melanoma: a micromorphometric study relating to prognosis and completion lymph node dissection.
    Debarbieux S; Duru G; Dalle S; Béatrix O; Balme B; Thomas L
    Br J Dermatol; 2007 Jul; 157(1):58-67. PubMed ID: 17501957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of factors beyond Breslow depth on predicting sentinel lymph node positivity in melanoma.
    Paek SC; Griffith KA; Johnson TM; Sondak VK; Wong SL; Chang AE; Cimmino VM; Lowe L; Bradford CR; Rees RS; Sabel MS
    Cancer; 2007 Jan; 109(1):100-8. PubMed ID: 17146784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma.
    Azimi F; Scolyer RA; Rumcheva P; Moncrieff M; Murali R; McCarthy SW; Saw RP; Thompson JF
    J Clin Oncol; 2012 Jul; 30(21):2678-83. PubMed ID: 22711850
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sentinel lymph node status is the most important prognostic factor for thick (> or = 4 mm) melanomas.
    Gutzmer R; Satzger I; Thoms KM; Völker B; Mitteldorf C; Kapp A; Bertsch HP; Kretschmer L
    J Dtsch Dermatol Ges; 2008 Mar; 6(3):198-203. PubMed ID: 18093216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sentinel lymph node micrometastasis and other histologic factors that predict outcome in patients with thicker melanomas.
    Cherpelis BS; Haddad F; Messina J; Cantor AB; Fitzmorris K; Reintgen DS; Fenske NA; Glass LF
    J Am Acad Dermatol; 2001 May; 44(5):762-6. PubMed ID: 11312421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinicopathologic predictors of sentinel lymph node metastasis in thin melanoma.
    Han D; Zager JS; Shyr Y; Chen H; Berry LD; Iyengar S; Djulbegovic M; Weber JL; Marzban SS; Sondak VK; Messina JL; Vetto JT; White RL; Pockaj B; Mozzillo N; Charney KJ; Avisar E; Krouse R; Kashani-Sabet M; Leong SP
    J Clin Oncol; 2013 Dec; 31(35):4387-93. PubMed ID: 24190111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survival analysis and clinicopathological factors associated with false-negative sentinel lymph node biopsy findings in patients with cutaneous melanoma.
    Nowecki ZI; Rutkowski P; Nasierowska-Guttmejer A; Ruka W
    Ann Surg Oncol; 2006 Dec; 13(12):1655-63. PubMed ID: 17016755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic implications of anatomic location of primary cutaneous melanoma of 1 mm or thicker.
    Callender GG; Egger ME; Burton AL; Scoggins CR; Ross MI; Stromberg AJ; Hagendoorn L; Martin RC; McMasters KM
    Am J Surg; 2011 Dec; 202(6):659-64; discussion 664-5. PubMed ID: 22137134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors predicting the risk of in-transit recurrence after sentinel lymphonodectomy in patients with cutaneous malignant melanoma.
    Kretschmer L; Beckmann I; Thoms KM; Mitteldorf C; Bertsch HP; Neumann C
    Ann Surg Oncol; 2006 Aug; 13(8):1105-12. PubMed ID: 16865591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In transit/local recurrences in melanoma patients after sentinel node biopsy and therapeutic lymph node dissection.
    Rutkowski P; Nowecki ZI; Zurawski Z; Dziewirski W; Nasierowska-Guttmejer A; Switaj T; Ruka W
    Eur J Cancer; 2006 Jan; 42(2):159-64. PubMed ID: 16324835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.